{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.9","upperLimit":"11.3","value":"2.96"},{"groupId":"OG001","lowerLimit":"0.9","upperLimit":"12.9","value":"3.01"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"46"}],"units":"Participants"}],"description":"Time to Best Response was measured as the time in months from the first dose of study treatment to the date of first documented documentation of a confirmed response of partial response (PR) or better.","dispersionType":"Full Range","groups":[{"description":"In phase 2, ixazomib 4.0 mg fixed dose, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 4.0 mg fixed dose, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.","id":"OG000","title":"Phase 2: Ixazomib 4.0 mg + Lenalidomide + Dexamethasone"},{"description":"In phase 2, ixazomib 4.0 mg fixed dose, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once, on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once, on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 4.0 mg fixed dose, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity. Includes 3 participants who received 2.23 mg/m\\^2 in Phase 1.","id":"OG001","title":"Phase 2: Ixazomib 4.0 mg/2.23 + Lenalidomide + Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"Participants form the response-evaluable population, defined as all patients who received at least one dose of ixazomib, had measurable disease at baseline, and at least one post-baseline disease assessment, with available data.","reportingStatus":"POSTED","timeFrame":"Up to 787 days","title":"Phase 2: Time to Best Response","type":"SECONDARY","unitOfMeasure":"months"}